8-K: Champions Oncology Reports Record Revenue, Positive EBITDA

Champions Oncology announced record annual revenue of $59.4 million and positive Adjusted EBITDA for the fiscal year ended April 30, 2026, alongside a 12% increase in fourth-quarter revenue.

Summary

• Champions Oncology achieved a record annual revenue of $59.4 million for the fiscal year ended April 30, 2026, a 4% increase from the previous year.
• The company reported positive Adjusted EBITDA for all four quarters of fiscal year 2026, totaling $1.6 million for the year.
• Fourth-quarter revenue rose 12% year-over-year to $13.8 million.
• Oncology services margin improved to 51% in the fourth quarter, up from 41% in the prior year period.
• Investments were made in radiopharmaceuticals, the data platform, and the commercial organization.
• The company ended the quarter with $4.9 million in cash and no debt.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting record revenue and consistent positive EBITDA, despite increased investments and a year-over-year decrease in annual Adjusted EBITDA.

Positives

• Record annual revenue of $59.4 million achieved for fiscal year 2026.
• Fourth consecutive quarter of positive Adjusted EBITDA, with $1.6 million for the full fiscal year.
• Fourth-quarter revenue increased by 12% to $13.8 million compared to the prior year.
• Oncology services margin improved significantly to 51% in Q4 FY2026 from 41% in Q4 FY2025.
• Company ended the fiscal year with $4.9 million in cash and no debt.
• Cost of oncology revenue decreased by 6% in the fourth quarter due to cost discipline and in-house transition of radiopharmaceutical activities.

Negatives

• Total operating expenses increased by $8.2 million to $60.6 million for fiscal year 2026, primarily due to higher outsourced radiopharmaceutical costs and investments in commercial and data platforms.
• Adjusted EBITDA decreased to $1.6 million for fiscal year 2026 from $7.1 million in the prior fiscal year.
• Oncology services margin decreased slightly to 48% for the full fiscal year 2026 from 50% in the prior year, attributed to temporary outsourced laboratory costs.
• Net cash used in operating activities for the quarter was approximately $2.2 million, driven by working capital timing, including higher accounts receivable and reduced deferred revenue.

Risks

• The company's actual results could differ materially from those anticipated in forward-looking statements due to many unforeseen factors.
• Continued investment in radiopharmaceuticals, the data platform, and the commercial organization may impact short-term profitability.
• The absence of a significant data licensing transaction from the prior year impacted revenue comparisons.
• Increased research and development expenses, up 33% year-over-year, reflect investments in the data platform.

Future Outlook

The company is focused on investing in radiopharmaceuticals, its data platform, and commercial organization to support future growth and strengthen its competitive position. Management believes these investments will expand opportunities for long-term growth.

Management Comments

• "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth."
• "Our core research services business performed well as we advanced several strategic initiatives, including expanding our radiopharmaceutical platform, strengthening our data strategy, making meaningful progress toward the commercial application of Corellia's technology, and growing our commercial organization."
• "We believe these investments strengthen our competitive position and expand our opportunities for long-term growth, and we remain focused on building on this momentum."
• "Our financial results for fiscal 2026 reflect the strength of our core research services business."
• "We delivered record annual revenue despite the absence of the prior year's significant data licensing transaction and generated positive Adjusted EBITDA in each quarter of the fiscal year, reflecting our disciplined approach to managing our cost structure while continuing to invest in our strategic initiatives."
• "We remain focused on allocating capital prudently to support the Company's long-term growth objectives."

Industry Context

StockSavvy.ai notes that Champions Oncology's performance, particularly its record revenue and focus on expanding its radiopharmaceutical and data platform capabilities, aligns with broader industry trends in oncology research and development, where precision medicine and advanced data analytics are increasingly critical for drug discovery and development.

Comparison to Industry Standards

• The oncology services margin of 51% in Q4 FY2026 is a strong indicator of operational efficiency, especially when compared to industry benchmarks where margins can vary significantly based on service mix and scale.
• Achieving positive Adjusted EBITDA for four consecutive quarters demonstrates financial discipline, a key metric investors scrutinize in the R&D services sector.
• The company's investment in radiopharmaceuticals and data platforms reflects a strategic alignment with leading biopharmaceutical companies that are prioritizing these advanced therapeutic and analytical areas.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic investments, offset by short-term impact on profitability metrics like annual Adjusted EBITDA.
• Employees: Continued investment in commercial organization may lead to growth opportunities.
• Customers: Continued investment in R&D and data platforms likely to enhance service offerings.
• Suppliers: Increased in-house radiopharmaceutical activities may shift demand for outsourced services.

Next Steps

• Continue investing in radiopharmaceutical platform, data platform, and commercial organization.
• Focus on building on current momentum for long-term growth.
• Allocate capital prudently to support long-term growth objectives.
• Full details of financial results will be available in the Form 10-K by July 29, 2026.

Key Dates

Recommendation

The company demonstrates strong revenue growth and operational improvements, evidenced by record annual revenue and improved quarterly margins. However, the significant decrease in annual Adjusted EBITDA compared to the prior year, coupled with increased operating expenses due to strategic investments, warrants a cautious 'hold' rating until the impact of these investments on profitability becomes clearer.

Keywords

Oncology Research Models, Translational Solutions, Radiopharmaceuticals, Data Platform, Preclinical Research, Clinical Trials, Biopharmaceutical Services, PDX Models